

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 10, 2006.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1648
Patent Application
Docket No. USF-T156X
Serial No. 10/073,065

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Myron G. Hill
Art Unit : 1648
Applicants : Shyam Mohapatra, Mukesh Kumar, Shau-Ku Huang, Kam W. Leong
Serial No. : 10/073,065
Filed : February 12, 2002
Conf. No. : 2390
For : Gene Expression Vaccine

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicants have not submitted copies of the U.S. patents or published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the

02/15/2006 HVUONG1 00000031 190065 10073065

01 FC:1806 180.00 DA

J:\USFT156X\SIDS4.pto.doc/DNB/mv

mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/073,065	
			Filing Date	February 12, 2002	
			First Named Inventor	Shyam Mohapatra	
			Art Unit	1648	
			Examiner Name	Myron G. Hill	
Sheet	1	of	2	Attorney Docket Number	USF-T156X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,900,299 B1	05-31-2005	Mohapatra et al.	All
	U2	US-6,489,306 B2	12-03-2002	Mohapatra et al.	All
	U3	US-2005/0272650 A1	12-08-2005	Mohapatra	All
	U4	US-2005/0266093 A1	12-01-2005	Mohapatra	All
	U5	US-2005/0159385 A1	07-21-2005	Mohapatra	All
	U6	US-2003/0198624 A1	10-23-2003	Mohapatra et al.	All
	U7	US-2001/0006951 A1	07-05-2001	Mohapatra et al.	All
	U	US-			
	U	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/073,065
				Filing Date	February 12, 2002
				First Named Inventor	Shyam Mohapatra
				Group Art Unit	1648
				Examiner Name	Myron G. Hill
Sheet	2	of	2	Attorney Docket Number	USF-T156X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BARENDT, M. <i>et al.</i> "Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation" <i>J Infections Diseases</i> , 2004, 189:1866-1872.	
	R2	BIANCO, I. <i>et al.</i> "Chitosan-induced phospholipase A ₂ activation and arachidonic acid mobilization in P388D ₁ macrophages" <i>FEBS Letters</i> , 2000, 466:292-294.	
	R3	Centers for Disease Control and Prevention, 1999, Update: Respiratory syncytial virus activity—United States, 1998-1999 season.	
	R4	KNEYBER, M. <i>et al.</i> "Treatment and prevention of respiratory syncytial virus infection" <i>Eur. J. Pediatr</i> , 2000, 159:399-411.	
	R5	NICHOLAS, J.A. <i>et al.</i> "Cytolytic T-lymphocyte responses to respiratory syncytial virus: Effector cell phenotype and target proteins" <i>J. Virology</i> , 1990, 64:4232-4241.	
	R6	OPENSHAW, P. and TREGONING, J. "Immune responses and disease enhancement during respiratory syncytial virus infection" <i>Clin Microbiol Rev</i> , 2005, 18:541-555.	
	R7	OPENSHAW, P. <i>et al.</i> "Immunopathogenesis of vaccine-enhanced RSV disease" <i>Vaccine</i> , 2002, 20:S27-S31.	
	R8	OTTERLEI, M. <i>et al.</i> "Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14" <i>Vaccine</i> , 1994, 12:825-832, abstract.	
	R9	PIEDRA, P. "Clinical experience with respiratory syncytial virus vaccines" <i>Pediatr Infect Dis J</i> , 2003, 22:S94-S99.	
	R10	RICHARDSON, S. <i>et al.</i> "Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA" <i>Intn'l J Pharmaceutics</i> , 1999, 178:231-243.	
	R		
	R		
	R		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.